03/08/2021
preclinics is attending the Immunotherapy for Infectious Diseases Conference 20-23th of June, 2022 in Pavia at University of Pavia.
For more information please click (link: https://www.idimmunotherapy.com/).
More info…
UK B1.1.7 SARS-CoV-2 pseudoviruses
22/02/2021
**UK B1.1.7 SARS-CoV-2 pseudoviruses available for Neutralization assay: **Preclinics is offering its Customers the Pseudoviral Infection/Neutralization assay with recent mutated strain B1.1.7.
(image: 21b-05-014_b117-infection.jpg)
(image: pexels-cdc-3992933.jpg)
Photo by CDC from Pexels
10/08/2020
preclinics is developing assays for SARS-CoV-2 and COVID-19 research. Now our virus neutralizing assays are available to test the neutralizing effect of antibodies and sera. Assays for protease inhibitors, as well as in vivo models in K18-huACE2 mice will follow soon. For covid19 research we have a lung inflammation model established.
(image: noname015.jpg)
More info…
27/11/2020
COVID-19 Pseudovirus Infection and Neutralisation Service
Preclinics GmbH offers its customers Covid-19 pseudotyped viruses infection and neutralization services in vitro and ex vivo. This service is based on the crucial interaction of trimeric Spike protein of SARS-Cov2 with its eukaryotic counter receptor ACE2.
This service can be used for:
1. Screening patient serum for neutralizing antibodies
2. Validating inhibitors of the Spike-ACE2 interaction
3. COVID-19 vaccine development
**Assay lay out**
(image: neutralization-assay-layout_small.jpg)
More info…
